HIV patients get safer flu shot options in new vaccine trial

NCT ID NCT01008813

Completed Disease control Sponsor: French National Agency for Research on AIDS and Viral Hepatitis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two versions of the H1N1 flu vaccine in 306 people living with HIV. One vaccine included an adjuvant (a booster ingredient) and the other did not. The goal was to see which vaccine was safer and better at protecting against the flu. Participants were followed for one year after receiving one or two shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

CIC de Vaccinologie Cochin Pasteur, hôpital Cochin

Paris, 75679, France
Hopital du Kremlin Bicêtre Service de médecine interne

Kremlin Bicëtre, 94275, France
Hôpital Gustave Dron, Service Maladies Infectieuses

Tourcoing, 59208, France
Hôpital Henri Mondor

Créteil, 94010, France
Hôpital Saint-Louis

Paris, 75010, France
Service des Maladies Infectieuses et Tropicales, Hopital Tenon

Paris, 75020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.